Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 1.02% | 73.34 | 0.9% | $603.58m | |
| CELG | Celgene Corporation | 2.24% | 130.29 | 1.1% | $443.49m | |
| AMGN | Amgen Inc. | 1.14% | 170.07 | 1.1% | $408.88m | |
| BIIB | Biogen Inc. | 1.26% | 286.72 | 1.2% | $356.69m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 1.90% | 478.65 | 2.7% | $320.91m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 4.34% | 155.48 | 1.9% | $240.46m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 3.58% | 138.20 | 1.9% | $220.20m | |
| ILMN | Illumina, Inc. | 2.14% | 194.76 | 3.5% | $214.91m | |
| INCY | Incyte Corporation | 2.46% | 123.86 | 2.6% | $133.37m | |
| KITE | Kite Pharma, Inc. | 1.52% | 135.95 | 16.1% | $128.55m | |
| CLVS | Clovis Oncology, Inc. | 1.24% | 72.08 | 18.0% | $127.98m | |
| TSRO | TESARO, Inc. | 1.48% | 120.62 | 14.7% | $126.99m | |
| A | Agilent Technologies, Inc. | 1.93% | 62.93 | 1.5% | $121.42m | |
| BMRN | BioMarin Pharmaceutical Inc. | 1.07% | 81.46 | 4.4% | $105.18m | |
| SRPT | Sarepta Therapeutics, Inc. | 3.41% | 36.95 | 19.8% | $99.21m |
Company Profile
Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its products contain drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. The company provides small molecule drugs, peptides and other potential biologic drug candidates. It's drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, CA.